Dr. Jacob Rendell is an R&D Executive with over 13 years’ experience in the pharmaceutical industry. Currently, Rendell serves as the Chief Technology Officer of SuperTrans Medical, a late preclinical stage biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant (MDR) bacteria. Previously, he directed the Lifecycle management portfolio of global R&D in Teva’s API division, and led interdisciplinary and multinational R&D teams in API process development from laboratory scale to cost-efficient GMP production, with an emphasis on small molecules and peptide development. He also conducted medicinal chemistry research in hepatitis C for GSK, UK. Rendell’s expertise includes organic synthesis and catalysis, pharmaceutical development strategy, intellectual property value creation, regulatory affairs, risk and project management.
Rendell gained a PhD in Organic Chemistry from Imperial College London focussing on metal-mediated synthesis of chiral dendrimers and pincer complexes, following a 1st class honours Master’s degree in Chemistry at UMIST, Manchester UK. He recently completed his studies for an MBA, with a focus on Biomedical Entrepreneurship from the Hebrew University of Jerusalem. Dr. Rendell is the author of numerous peer-reviewed scientific articles and patents with antibiotic, antiviral, gastrointestinal and oncology applications.